In addition, acquired resistance to PARP inhibitors, which may result from a PARP inhibitor being a substrate of P-gp (P-glycoprotein) and BCRP (breast cancer resistance protein) [8–10], has been reported to occur in most patients with advanced cancer who have received this class of agents [11]. Here, PARP1 is linked to cancer.